SCHEMBL281571

SCHEMBL281571

COc1cc([N+](=O)[O-])ccc1S(=O)(=O)N1CCCCC1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 3/20 0.65
ALDH1A1 P00352 9/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
MEN1 O00255 1/20 0.64
KMT2A Q03164 1/20 0.64
NPSR1 Q6W5P4 2/20 0.62
HPGD P15428 1/20 0.62
TSHR P16473 4/20 0.61
GAA P10253 1/20 0.61
NPBWR1 P48145 1/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 2/20 0.61
CYP2C19 P33261 2/20 0.61
CYP2C9 P11712 1/20 0.61
CYP19A1 P11511 1/20 0.57
HTT P42858 1/20 0.55
LMNA P02545 3/20 0.53
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754736 0.90 ALDH1A1 (0.67) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL10572672 0.88 ALDH1A1 (0.60) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1HPGD
SCHEMBL16305329 0.87 HTT (0.60) ALDH1A1SMN1; SMN2MEN1KMT2ANPSR1
SCHEMBL10126517 0.82 L3MBTL1 (0.77) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL15657217 0.81 ALDH1A1 (0.70) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL25920390 0.81 ALDH1A1 (0.79) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL11509427 0.80 PKM (0.56) ALDH1A1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL23326940 0.80 L3MBTL1 (0.97) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL29451251 0.80 L3MBTL1 (0.97) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL29452168 0.79 ALDH1A1 (0.61) MCOLN3ALDH1A1SMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-2428508-B9 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2016-04-20 EP disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 MCOLN3 2528/4885ALDH1A1 1554/4885SMN1; SMN2 4467/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 MCOLN3 2528/4885ALDH1A1 1554/4885SMN1; SMN2 4467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.